

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 21, 2011**

**IntelGenx Technologies Corp.**  
*(Exact name of registrant as specified in charter)*

**Delaware**  
*(State or other jurisdiction of  
incorporation or organization)*

**000-31187**  
*(Commission File No.)*

**87-0638336**  
*(IRS Employer  
Identification No.)*

**6425 Abrams, Ville Saint Laurent, Quebec, H4S 1X9 Canada**  
*(Address of principal executive offices)*

Registrant's telephone number, including area code: **(514) 331-7440**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

### **Item 1.01 Entry Into a Material Definitive Agreement.**

As previously reported by IntelGenx Technologies Corp. (the "Company") in its Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2011 (the "Prior Report"), on June 3, 2011 the Company entered into a definitive securities purchase agreement with certain accredited and institutional investors (collectively, the "Investors") for the issuance and sale in a private placement transaction (the "US Private Offering") of 2,582,536 shares (the "Shares") of the Company's common stock, par value \$0.00001 per share (the "Common Stock"), at a per share purchase price of \$0.67, and three-year warrants (the "Warrants") to purchase up to 1,291,268 shares of Common Stock at an exercise price of \$0.74 per share, for aggregate gross proceeds of approximately \$1.7 million.

In the Prior Report, the Company also disclosed that it intended to enter into a definitive subscription agreement solely with Canadian investors for the issuance and sale in a concurrent non-brokered private placement transaction (the "Canadian Private Offering") of up to an additional \$1.5 million in Shares and Warrants under the same terms and conditions as the US Private Offering. On June 21, 2011, the Company entered into definitive subscription agreements with such Canadian investors for the issuance and sale of 2,238,806 Shares and Warrants to purchase up to 1,119,403 shares of Common Stock for aggregate gross proceeds of approximately \$1.5 million.

The US and Canadian Private Offerings were consummated on June 21, 2011 (the "Closing Date") pursuant to which the Company received aggregate gross proceeds from the US and Canadian Private Offerings of approximately \$3.2 million, before deducting offering expenses. The Company intends to use the net proceeds from the sale of the Shares and Warrants pursuant to the US and Canadian Private Offerings for general corporate purposes.

Rodman & Renshaw, LLC acted as the exclusive placement agent for the US Public Offering. On the Closing Date, the Company paid/issued to Rodman & Renshaw, LLC or its designees: (i) cash commissions in the amount of \$121,120.85, representing 7% of the aggregate gross proceeds received by the Company in the US Private Offering, plus expenses in the amount of \$24,982.38; and (ii) warrants (the "Placement Agent Warrants") to purchase 180,778 shares of Common Stock, representing 7% of the amount of Shares sold in the US Private Offering.

Also on the Closing Date, the Company paid/issued to each of Haywood Securities Inc. and Raymond James Ltd. in connection with the Canadian Private Offering: (i) cash finder's fee in the amount of \$90,930 and \$14,070 respectively, representing 7% of the aggregate gross proceeds received by the Company in the Canadian Private Offering; and (ii) warrants to purchase 135,716 and 21,000 shares of Common Stock respectively, representing 7% of the amount of Shares sold in the Canadian Private Offering.

The foregoing is a summary of the consummation of the US and Canadian Private Offerings and not a complete discussion thereof. Accordingly, the foregoing is qualified in its entirety by reference to the full text of the Prior Report, together with the full text of each agreement and other documents filed as exhibits to the Prior Report, which are incorporated herein by reference.

On June 22, 2011, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.2 and incorporated herein by reference.

### **Item 3.02 Unregistered Sales of Equity Securities.**

The disclosure set forth in Item 1.01 to this Current Report is incorporated into this item by reference. On the Closing Date, the Company's issuance of the Shares, Warrants and Placement Agent Warrants was made in reliance upon the exemption from registration for non-public offerings under §4(2) of the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

(a) Financial statements of businesses acquired .

Not applicable.

(b) Pro forma financial information .

Not applicable.

(c) Shell company transactions .

Not applicable.

(d) Exhibits .

<b>Exhibit Number</b>	<b>Description</b>
4.1	Form of Warrant (incorporated by reference to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2011).
10.1	Form of Securities Purchase Agreement (incorporated by reference to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2011).
10.2	Form of Registration Rights Agreement (incorporated by reference to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2011).
99.1	Press Release of IntelGenx Technologies Corp. dated as of June 3, 2011 (incorporated by reference to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2011).
99.2	<a href="#">Press Release of IntelGenx Technologies Corp. dated as of June 22, 2011.</a>

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGEX TECHNOLOGIES CORP.**  
(Registrant)

By: /s/ Horst Zerbe

Name: Horst G. Zerbe

Title: President and Chief Executive Officer

Date: June 22, 2011



## IntelGenx Announces Closing of Private Placements

SAINT LAURENT, QUEBEC -- (Marketwire – June 22, 2011) -- IntelGenx Technologies Corp. (TSX-V: [IGX](#)) (OTC.BB: [IGXT](#)) (the “Company” or “IntelGenx”) today announced that it has closed private placement offerings totaling approximately 4.8 million shares (the “Shares”) of common stock (the “Common Stock”) at a per share purchase price of US\$0.67, and three-year warrants (the “Warrants”) to purchase up to approximately 2.4 million shares of Common Stock at an exercise price of US\$0.74 per share, for aggregate gross proceeds of approximately US\$3.2 million.

As previously announced, on June 3, 2011 the Company entered into a definitive securities purchase agreement with certain accredited and institutional investors for the issuance and sale in a private placement transaction (the “US Private Offering”) of 2,582,536 Shares and Warrants to purchase up to 1,291,268 shares of Common Stock, for aggregate gross proceeds of approximately \$1.7 million.

The Company also previously announced that it intended to enter into a definitive subscription agreement solely with Canadian investors for the issuance and sale in a concurrent non-brokered private placement transaction (the “Canadian Private Offering”) of up to an additional \$1.5 million in Shares and Warrants under the same terms and conditions as the US Private Offering. On June 21, 2011, the Company entered into definitive subscription agreements with such Canadian investors for the issuance and sale of 2,238,806 Shares and Warrants to purchase up to 1,119,403 shares of Common Stock, for aggregate gross proceeds of approximately \$1.5 million.

The US and Canadian Private Offerings were consummated on June 21, 2011 (the “Closing Date”) pursuant to which the Company received aggregate gross proceeds from the US and Canadian Private Offerings of approximately \$3.2 million, before deducting offering expenses. The Company intends to use the net proceeds from the sale of the Shares and Warrants pursuant to the US and Canadian Private Offerings for general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODM - News), acted as the exclusive placement agent for the US Public Offering. On the Closing Date, the Company paid/issued to Rodman & Renshaw, LLC or its designees: (i) cash commissions in the amount of \$121,120.85, representing 7% of the aggregate gross proceeds received by the Company in the US Private Offering, plus expenses in the amount of \$24,982.38; and (ii) warrants to purchase 180,778 shares of Common Stock, representing 7% of the amount of Shares sold in the US Private Offering.

Also on the Closing Date, the Company paid/issued to each of Haywood Securities Inc. and Raymond James Ltd. in connection with the Canadian Private Offering: (i) cash finder’s fees in the amount of \$90,930 and \$14,070 respectively, representing 7% of the aggregate gross proceeds received by the Company in the Canadian Private Offering; and (ii) warrants to purchase 135,716 and 21,000 shares of Common Stock respectively, representing 7% of the amount of Shares sold in the Canadian Private Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the US and Canadian Private Offerings.

### About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx’ research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at [www.intelgenx.com](http://www.intelgenx.com).

**Forward Looking Statements:**

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2010, filed with the United States Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov), and also filed with Canadian securities regulatory authorities and [www.sedar.com](http://www.sedar.com). IntelGenx assumes no obligation to update any such forward-looking statements.

*Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor disapproved the contents of this press release.*

**CONTACT:**

Dr. Horst G. Zerbe,  
President and CEO  
IntelGenx Technologies Corp.  
T: +1 514-331-7440 (ext. 201)  
F: +1 514-331-0436  
[horst@intelgenx.com](mailto:horst@intelgenx.com)  
[www.intelgenx.com](http://www.intelgenx.com)

---